IPM Take
MOGAD has spent years in a regulatory grey zone: recognised as a distinct neuroimmune disease, capable of producing severe and permanent disability, but without a medicine specifically approved for it. Clinicians have therefore had to build long-term prevention strategies largely from off-label immunotherapies.
FDA Priority Review for satralizumab could change that architecture. The strongest point is not the designation itself but the Phase III result underneath it: Roche reported a 68% reduction in first-relapse risk. That is the kind of outcome that matters in a disease where another attack may mean another piece of neurological function lost.
Executive Summary
FDA granted Priority Review to Roche’s supplemental biologics application for Enspryng, satralizumab, in MOGAD. The filing is supported by the Phase III METEOROID trial, which met its primary endpoint and showed a 68% reduction in first adjudicated relapse risk versus placebo. At week 48, 87% of satralizumab-treated participants were relapse-free compared with 67% receiving placebo.
Roche also reported improvements in annualised relapse rate, MRI lesion activity and rescue-treatment use. FDA’s target decision date is 10 January 2027. If approved, Roche says satralizumab would be the first disease-modifying treatment specifically approved for MOGAD in the United States.
Why it matters
- Patients / advocates: In MOGAD, relapse prevention can mean preserving vision, mobility and neurological independence.
- Clinicians: An approved therapy could reduce dependence on improvised off-label long-term immunotherapy strategies.
- Regulators: The application tests a substantial Phase III relapse-prevention package in a rare neuroimmune condition with no approved treatment.
- Payers: Approval would address regulatory uncertainty, but coverage rules and specialist eligibility could still restrict access.
Rare neuroimmune diseases expose an uncomfortable contradiction in modern medicine. A clinician can know exactly what disease a patient has, understand that recurrent attacks are dangerous, and still be forced to construct treatment from medicines formally approved for other conditions.
MOGAD has lived in that space. It can attack the optic nerves, spinal cord and brain, and recovery after an attack is not guaranteed. The logic of treatment is therefore unusually clear: preventing another attack may mean preventing disability that cannot later be repaired.
METEOROID gives satralizumab a serious regulatory case. Roche reports not only a statistically significant reduction in relapse risk, but fewer MRI lesions and less rescue-treatment use, with safety findings consistent with the established satralizumab experience in NMOSD.
Approval, however, will expose the next system failure. MOG antibody testing, specialist neuroimmunology services and referral pathways remain uneven. A first approved treatment cannot prevent an attack in a patient who is still being passed between incorrect diagnoses.
The medicine may be approaching the finish line. The MOGAD care pathway is not.
